Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Longgang Wang, Bing Liu, Luguang Liu, Liqing Liu, Rong Li, Shumei Han, Xu Sun, Bo Bi, Yuanlin Sun, Dong Sun, Jie Chai
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Clinical and Translational Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet